Study of variation in price of various antidiabetic drugs available in Indian market

Amit Padmakar Date, Harshal M. Mahajan, Amruta V. Dashputra, Rahul R. Bhosale

Abstract


Background: Diabetes mellitus in early age is on the alarming rise in India, requiring lifelong treatment. There is a wide range of variation in the prices of antidiabetic drugs marketed in India. Hence, we decided to study price variations in the oral antidiabetic drugs available, either singly or in combination, and number of manufacturing companies for each, and to evaluate the difference in cost of different brands of same active drug by calculating percentage variation of cost.

Methods: Cost of a particular drug being manufactured by different companies, in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” July-October 2014 and “Indian Drug Review” July 2014. The difference in the maximum and minimum price of the same drug, manufactured by different pharmaceutical companies and percentage variation in price was calculated.

Results: Percentage price variation among different group of drugs was found to be as follows: in sulfonylureas, it was highest in glimepiride 2 mg 836.44%, among biguanides - metformin 500 mg 245.55%, among thiazolidionediones-pioglitazone 15 mg 600%, among α glucosidase inhibitors - voglibose 284.61% and meglitinides - repaglinide 0.5 mg 181.40%. Among combination therapy glimepiride 1 mg + metformin 500 mg 366.66%, pioglitazone + metformin 207.51%, pioglitazone + glimepiride 268.42% showed maximum variation in price.

Conclusion: The average percentage price variation of different brands of the same oral antidiabetic drug manufactured in India is very wide. The appropriate changes in the government policy, sensitizing the prescribers about cost of therapy and proper management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative economic consequences.


Keywords


Price variation, Antidiabetic drugs, Branded generics

Full Text:

PDF

References


Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.

Patel D, Thiyagu R, Surulivelrajan M, Patel H, Pandey S. Price variability among the oral antibiotics available in a South Indian Tertiary Care Hospital. J Clin Diagn Res. 2009;3(6):1871-5.

Indrayan A. Epidemiology of hypertension. J Assoc Physicians India. 1994;42(2):175-6.

Mahal A, Karan A, Engelgau M. The Economic Implications of Non-communicable Disease for India. Washington, DC: World Bank; 2010.

Jana S, Mondal P. Pharmacoeconomics: the need to sensitize undergraduate medical students. Indian J Pharmacol. 2005;37(5):277-8.

National List of Essential Medicines, 2011. Available from: http://www.mohfw.nic.in/WriteReadData/1892s/7364497. Accessed 10 September 2014.

Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35-8.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K, editors. A Textbook of Clinical Pharmacy Practice. 1st Edition. Himayatnagar, Hyderabad: Orient Longman; 2004: 72-3.

Karve AV, Chattar KB. Cost analysis study of oral antihypertensive agents available in Indian Market. Int J Basic Clin Pharmacol. 2014;3(3):479-84.

Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian Market. Int J Med Res Health Sci. 2014;2(1):63-9.

World Health Organisation. Essential drugs and medicines: Drug finance. Available at: http://www.whoindia.org/EN/Section2/Section/Section160_959.html. Accessed 12 September 2014.

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.

Sarkar PK. A rational drug policy. Indian J Med Ethics. 2004;12:30-5.

Roy V, Rewari S. Ambiguous drug pricing: a physician’s dilemma. Indian J Pharmacol. 1998;30(6):404-7.

Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics. 1992;2(6):449-55.

Berki SE, Richards JW, Weeks HA. The mysteries of prescription pricing in retail pharmacies. Med Care. 1977;15(3):241-50.